<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455830</url>
  </required_header>
  <id_info>
    <org_study_id>UMIN000014903-Cytokines</org_study_id>
    <nct_id>NCT02455830</nct_id>
  </id_info>
  <brief_title>Cytokines Associated With Cord Blood Cell Therapy for Neonatal Encephalopathy</brief_title>
  <official_title>A Study to Determine if Autologous Umbilical Cord Blood Cell Therapy Alters Serum Levels of Cytokines and Trophic Factors in Neonatal Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neonatal Encephalopathy Consortium, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Osaka City University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yodogawa Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kurashiki Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osaka City General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saitama Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Child Health and Development, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tokyo Women's Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neonatal Encephalopathy Consortium, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a observational study to assess the effects of and to explore the mechanisms of&#xD;
      autologous umbilical cord blood cell therapy for neonatal encephalopathy by way of measuring&#xD;
      serum cytokines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects and mechanisms of umbilical cord blood cell therapy for perinatal brain injury&#xD;
      are not well understood. This is a multicenter study to measure serum levels of inflammatory&#xD;
      cytokines and trophic factors associated with perinatal brain injury and repair in term&#xD;
      gestation newborns with neonatal encephalopathy (hypoxic-ischemic encephalopathy). This study&#xD;
      proceeds along with the study &quot;Autologous cord blood cell therapy for neonatal encephalopathy&#xD;
      (ClinicalTrials.gov identifier: NCT02256618)&quot;. Blood samples are obtained before the first&#xD;
      cell infusion, and subsequently 2h, 24h, 48h, and 7 days after the first cell infusion. Blood&#xD;
      samples are obtained in the same manner from newborns with neonatal encephalopathy who are&#xD;
      not receiving the cell therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in serum levels of cytokines and trophic factors</measure>
    <time_frame>From birth up to 10 days of age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association with neuroimaging and neurodevelopmental functional outcome</measure>
    <time_frame>18 months</time_frame>
    <description>Neuroimaging at 12 months of age and neurodevelopmental function at 18 months of age will be assessed whether they are associated with serum levels of cytokines and trophic factors during the early neonatal period.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Neonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy)</condition>
  <arm_group>
    <arm_group_label>Cell-treated</arm_group_label>
    <description>Infants with encephalopathy who receive autologous umbilical cord blood cell therapy along with therapeutic hypothermia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cooled only</arm_group_label>
    <description>Infants with encephalopathy who receive therapeutic hypothermia only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous cord blood cell therapy</intervention_name>
    <description>The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.</description>
    <arm_group_label>Cell-treated</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infants with encephalopathy who meet the inclusion criteria of therapeutic hypothermia,&#xD;
        either those who receive the cell therapy or those who do not.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Infants are eligible if they meet all the following inclusion criteria except 4.&#xD;
&#xD;
          1. ≥36 weeks gestation&#xD;
&#xD;
          2. Either a 10-minute Apgar score ≤5, continued need for resuscitation for at least 10&#xD;
             minutes, or severe acidosis, defined as pH &lt;7.0 or base deficit ≥16 mmol/L in a sample&#xD;
             of umbilical cord blood or any blood during the first hour after birth&#xD;
&#xD;
          3. Moderate to severe encephalopathy (Sarnat II to III)&#xD;
&#xD;
          4. A moderately or severely abnormal background amplitude-integrated EEG (aEEG) voltage,&#xD;
             or seizures identified by aEEG, if monitored&#xD;
&#xD;
          5. Up to 24 hours of age&#xD;
&#xD;
          6. A person with parental authority must have consented for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known major congenital anomalies, such as chromosomal anomalies, heart diseases&#xD;
&#xD;
          2. Major intracranial hemorrhage identified by brain ultrasonography or computed&#xD;
             tomography&#xD;
&#xD;
          3. Severe growth restriction, with birth-weight less than 1800 g&#xD;
&#xD;
          4. Severe infectious disease, such as sepsis&#xD;
&#xD;
          5. Infants judged critically ill and unlikely to benefit from neonatal intensive care&#xD;
             including hypothermia by the attending neonatologist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haruo Shintaku, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Osaka City University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yodogawa Christian Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>533-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal encephalopathy</keyword>
  <keyword>Hypoxic-ischemic encephalopathy</keyword>
  <keyword>Newborn infants</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Trophic factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

